Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93040
標題: Correlation between molecular phenotypes,chemotherapy response and prognosis in canine malignant mammary tumors
犬惡性乳腺瘤之分子表型與化療反應及預後間的相關性
作者: Li-Ren Wang
王俐人
關鍵字: 
引用: Alison, M.R., 1995. Assessing cellular proliferation: what's worth measuring? Hum Exp Toxicol 14, 935-944. Allen, S.W., Prasse, K.W., Mahaffey, E.A., 1986. Cytologic differentiation of benign from malignant canine mammary tumors.Vet Pathol 23, 649-655. Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M., 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11, 155-168. Arafah, B.M., Finegan, H.M., Roe, J., Manni, A., Pearson, O.H., 1982. Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology 111, 584-588. Ayers, M., Symmans, W.F., Stec, J., Damokosh, A.I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., Valero, V., Royce, M., Arun, B., Whitman, G., Ross, J., Sneige, N., Hortobagyi, G.N., Pusztai, L., 2004. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22, 2284-2293. Balleine, R.L., Earl, M.J., Greenberg, M.L., Clarke, C.L., 1999. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 79, 1564-1571. Bardou, V.J., Arpino, G., Elledge, R.M., Osborne, C.K., Clark, G.M., 2003. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21, 1973-1979. Benjamin, S.A., Lee, A.C., Saunders, W.J., 1999. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol 36, 423-436. Bottini, A., Berruti, A., Bersiga, A., Brizzi, M.P., Bruzzi, P., Aguggini, S., Brunelli, A., Bolsi, G., Allevi, G., Generali, D., Betri, E., Bertoli, G., Alquati, P., Dogliotti, L., 2001. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85, 1106-1112. Braun, N., Papadopoulos, T., Muller-Hermelink, H.K., 1988. Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B Cell Pathol Incl Mol Pathol 56, 25-33. Brown, R.W., Allred, C.D., Clark, G.M., Osborne, C.K., Hilsenbeck, S.G., 1996. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2, 585-592. Bruno, S., Darzynkiewicz, Z., 1992. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 25, 31-40. Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan, D., Conway, K., Karaca, G., Troester, M.A., Tse, C.K., Edmiston, S., Deming, S.L., Geradts, J., Cheang, M.C., Nielsen, T.O., Moorman, P.G., Earp, H.S., Millikan, R.C., 2006. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502. Carraway, K., Cantly, L.C., 1994. A neu acquaintance for erbB3 and erbB4 a role for receptor heterodimerization in growth signaling. Cell 78, 5-8. Casey, H.W., Giles, R.C., Kwapien, R.P., 1979. Mammary neoplasia in animals: pathologic aspects and the effects of contraceptive steroids. Recent Results Cancer Res 66, 129-160. Cattoretti, G., Becker, M.H., Key, G., Duchrow, M., Schlüter, C., Galle, J., Gerdes, J., 1992. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168, 357-363. Chang, C.C., Tsai, M.H., Liao, J.W., Chan, J.P.W., Wong, M.L., Chang, S.C., 2009. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. J Am Vet Med Assoc 235, 391-396. Chang, J.C., Wooten, E.C., Tsimelzon, A., Hilsenbeck, S.G., Gutierrez, M.C., Elledge, R., Mohsin, S., Osborne, C.K., Chamness, G.C., Allred, D.C., O'Connell, P., 2003. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369. Chang, S.C., Chang, C.C., Chang, T.J., Wong, M.L., 2005. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc.227, 1625-1629. Cheang, M.C., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P.S., Parker, J.S., Perou, C.M., Ellis, M.J., Nielsen, T.O., 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101, 736-750. Citron, M.L., Berry, D.A., Cirrincione, C., Hudis, C., Winer, E.P., Gradishar, W.J., Davidson, N.E., Martino, S., Livingston, R., Ingle, J.N., Perez, E.A., Carpenter, J., Hurd, D., Holland, J.F., Smith, B.L., Sartor, C.I., Leung, E.H., Abrams, J., Schilsky, R.L., Muss, H.B., Norton, L., 2003. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21, 1431-1439. Clarke, C.L., Sutherland, R.L., 1990. Progestin regulation of cellular proliferation. Endocrine Rev 11, 266-300. Clarke, R.B., Howell, A., Potten, C.S., Anderson, E., 1997. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57, 4987-4991. Conneely, O.M., Lydon, J.P., 2000. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 65, 571-577. Dahlman-Wright, K., Cavailles, V., Fuqua, S.A., Jordan, V.C., Katzenellenbogen, J.A., Korach, K.S., Maggi, A., Muramatsu, M., Parker, M.G.,Gustafsson, J.A., 2006. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58, 773-781. de Azambuja, E., Cardoso, F., de Castro, G.J., Colozza, M., Mano, M.S., Durbecq, V., Sotiriou, C., Larsimont, D., Piccart-Gebhart, M.J., Paesmans, M., 2007. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96, 1504-1513. De Potter, C.R., 1994. The neu oncogene: more than a prognostic indicator? HumPathol 25, 1264-1268. Delaunay, F., Pettersson, K., Tujague, M., Gustafsson, J.A., 2000. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58, 584–590. Deroo, B.J., Korach, K.S., 2006. Estrogen receptors and human disease. J Clin Invest 116, 561-570. Dhaliwal, G.K., England, G.C., Noakes, D.E., 1997. Immunocytochemical localization of oestrogen and progesterone receptors in the uterus of the normal bitch during oestrus and metoestrus. J Reprod Fertil Suppl 51, 167-176. Domagala, W., Markiewski, M., Harezga, B., Dukowicz, A., Osborn, M., 1996. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein . Clin Cancer Res 2, 147-154. Donnay, I., Rauïs, J., Devleeschouwer, N., Wouters-Ballman, P., Leclercq, G., Verstegen, J., 1995. Comparison of estrogen and progesterone receptor expression in normal and tumor mammary tissues from dogs. Am J Vet Res 56, 1188-1194. Dorn, C.R., Taylor, D.O., Schneider, R., Hibbard, H.H., Klauber, M.R., 2008. Surgery of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda Country. J Natl Cancer Inst 40, 307-318. Dowsett, M., Smith, I.E., Ebbs, S.R., Dixon, J.M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., Walsh, G.; IMPACT Trialists Group, 2007. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99, 167-170. Dressing, G.E., Hagan, C.R., Knutson, T.P., Daniel, A.R., Lange, C.A., 2009. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer 16, 351-361. du Manoir, S., Guillaud, P., Camus, E., Seigneurin, D., Brugal, G., 1991. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12, 455-463. Duchrow, M., Schlüter, C., Wohlenberg, C., Flad, H.D., Gerdes, J., 1996. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 29, 1-12. Earp, H.S., Dawson, T.L., Li, Q., Yu, H., 1995. Heterodimerization and bifunctional interaction between EGF receptor family members: A new signaling paradigm with implication for breast cancer research. Breast Cancer Res Treat 35, 115-132. Egenvall, A., Bonnett, B.N., Ohagen, P., Olson, P., Hedhammar, A., von Euler, H., 2005. Incidence of and survival after mammary tumors in a population of over 80,000 insuredfemale dogs in Sweden from 1995 to 2002. Prev Vet 69, 109-127. Ellis, M.J., Coop, A., Singh, B., Tao, Y., Llombart-Cussac, A., Jänicke, F., Mauriac, L., Quebe-Fehling, E., Chaudri-Ross, H.A., Evans, D.B., Miller, W.R., 2003. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63, 6523-6531. Enmark, E., Pelto-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., Fried, G., Nordenskjöld, M., Gustafsson, J.A., 1997. Human estrogen receptor beta-gene structure, chromosomal localization, and expressionpattern. J Clin Endocrinol Metab 82, 4258-4265. Eroles, P., Bosch, A., Pérez-Fidalgo, J.A., Lluch, A., 2012. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38, 698-707. Fichtinger-Schepman, A.M., van Dijk-Knijnenburg, H.C., van der Velde-Visser, S.D., Berends, F., Baan, R.A., Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion? Carcinogenesis 16, 2447-2453. Fidler, I.J., Brodey, R.S., 1967. The biological behavior of canine mammary neoplasms. J Am Vet Med Assoc 151, 1311-1318. Fonatsch, C., Duchrow, M., Rieder, H., Schlüter, C., Gerdes, J., 1991. Assignment of the human Ki-67 gene (MK167) to 10q25-qter. Genomics 11, 476-477. Fuqua, S.A., Fitzgerald, S.D., Chamness, G.C., Tandon, A.K., McDonnell, D.P., Nawaz, Z., O'Malley, B.W., McGuire, W.L., 1991. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51, 105–109. Gama, A., Alves, A., Schmitt, F., 2008. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 453, 123-132. Geraldes, M., Gärtner, F., Schmitt, F., 2000. Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumours. Vet Rec 146, 403-406. Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U., Stein, H., 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133, 1710-1715. Gerdes, J., Schwab, U., Lemke, H., Stein, H., 1983. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31, 13-20. Giangrande, P.H., McDonnell, D.P., 1999. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 54, 291-314. Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Mariani, G., Rodriguez, J., Carcangiu, M., Watson, D., Valagussa, P., Rouzier, R., Symmans, W.F., Ross, J.S., Hortobagyi, G.N., Pusztai, L,, Shak, S., 2005. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23, 7265-7277. Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thürlimann, B., Senn, H.J., Panel members, 2011. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22, 1736-1747. Graham, J.C., O'Keefe, D.A., Gelberg, H.B., 1999. Immunohistochemical assay for detecting estrogen receptors in canine mammary tumors. Am J Vet Res 60, 627-630. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.M., Argos, P., Chambon, P., 1986. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320, 134-139. Greene, G.L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., Shine, J., 1986. Sequence and expression of human estrogen receptor complementary DNA. Science 231, 1150-1154. Gustafson, D.L., Page, R.L., 2012. Cancer chemotherapy. In: Small Animal Clinical Oncology, Fifth Ed. Saunders Elsevier, Philadelphia, PA, USA, pp. 157-179. Hampe, J.F., Misdorp, W., 1974. Tumours and dysplasias of the mammary gland. Bull World Health Organ 50, 111-133. Harper-Wynne, C., Ross, G., Sacks, N., Salter, J., Nasiri, N., Iqbal, J., A'Hern, R., Dowsett, M., 2002. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11, 614-621. Hellmén, E., Bergström, R., Holmberg, L., Spångberg, I.B., Hansson, K., Lindgren, A., 1993. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases.Vet Pathol 30, 20-27. Horwitz, K.B., McGuire, W.L., 1975. Specific progesterone receptors in human breast cancer. Steroids 25, 497-505. Hsu, W.L., Huang, H.M., Liao, J.W., Wong, M.L., Chang, S.C., 2009. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene.Vet J 180, 116-123. Inaba, T., Takahashi, N., Matsuda, H., Imori, T., 1984. Estrogen and progesterone receptors and progesterone metabolism in canine mammary tumours. Nihon Juigaku Zasshi 46, 797-803. Itoh, T., Uchida, K., Ishikawa, K., Kushima, K., Kushima, E., Tamada, H., Moritake, T., Nakao, H., Shii, H., 2005. Clinicopathological survey of 101 canine mammary gland tumors: differences between small-breed dogs and others. J Vet Med Sci 67, 345-347. Kadthur, J.C., Rao, S., Sonnahallipura, B.M., Thimmanahalli, D.S., Laxmikanth, S.M., 2011. Prognostic Value of Ki 67 Proliferation Antigen in Canine Malignant Mammary Gland Tumors. Braz J Vet Pathol 4, 36-40. Karayannopoulou, M., Kaldrymidou, E., Constantinidis, T.C., Dessiris, A., 2005. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 133, 246-252. Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E., Yarden, Y., 1996. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15, 254-264. Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H., Chambon, P., 1990. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9, 1603-1614. Key, G., Becker, M.H., Baron, B., Duchrow, M., Schlüter, C., Flad, H.D., Gerdes, J., 1993. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68, 629-636. Kiessling, R., Wei, W.Z., Herrmann, F., Lindencrona, J.A., Choudhury, A., Kono, K., Seliger, B., 2002. Cellular Immunity to the Her-2/neu Protooncogene. Adv Cancer Res 85, 101-144. Kill, I.R., 1996. Localisation of the Ki-67 antigen within the nucleolus: Evidence for a fibrillarindeficient region of the dense fibrillar component. J Cell Sci 109, 1253-1263. Klapper, L.N., Glathe, S., Vaisman, N., Hynes, N.E., Andrews, G.C., Sela, M., Yarden, Y., 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96, 4995-5000. Kraus, W.L., Montano, M.M., Katzenellenbogen, B.S., 1993. Cloning of the rat progesterone receptor gene 59-region and identification of two functionally distinct promoters. Mol Endocrinol 7, 1603–1616. Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., Gustafsson, J.A., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93, 5925-5930. Kuiper, G.G., Gustafsson, J.A., 1997. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410, 87-90. Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., van der Burg, B., Gustafsson, J.A., 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139, 4252-4263. Kurzman, I.D., Gilbertson, S.R., 1986. Prognostic factors in canine mammary tumors. Semin Vet Med Surg (Small Anim) 1, 25-32. Lana, S.E., Rutteman, G.R., Withrow, S.J., 2007. Tumors of the mammary gland. In: Small Animal Clinical Oncology, Fourth Ed. Saunders Elsevier, Philadelphia, PA, USA, pp. 619-636. Lantinga-van Leeuwen, I.S., van Garderen, E., Rutteman, G.R., Mol, J.A., 2000. Cloning and cellular localization of the canine progesterone receptor: co-localization with growth hormone in the mammary gland. J Steroid Biochem Mol Biol 75, 219-228. Locker, G.Y., 1998. Hormonal therapy of breast cancer. Cancer Treat Rev 24, 221–240. Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P., Boisseau, M.R., 1991. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 12, 42-49. Lupu, R., Cardillo, M., Harris, L., Hijazi, M., Rosenberg, K., 1995. Interaction between ERBreceptors and heregulin in breast cancer tumor progression and drug resistance. Sem Cancer Biol 6, 135-145. Lydon, J.P., DeMayo, F.J., Funk, C.R., Mani, S.K., Hughes, A.R., Montgomery, C.A.J., Shyamala, G., Conneely, O.M., O'Malley, B.W., 1995. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9, 2266-2278. MacEwen, E.G., Patnaik, A.K., Harvey, H.J., Panko, W.B., 1982. Estrogen receptors in canine mammary tumors. Cancer Res 42, 2255-2259. MacEwen, E.G., Withrow, S., 1996. Tumors of the mammary gland. In: Small Animal Oncology, Second Ed. Saunders Elsevier, Philadelphia, PA, USA, pp. 356-372. Martin de las Mulas, J., Millán, Y., Dios, R., 2005. A prospective analysis of immunohistochemically determined estrogen receptor α and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol 42, 200-212. Martin de las Mulas, J., Ordás, J., Millán, M.Y., Chacón, F., De Lara, M., Espinosa de los Monteros, A., Reymundo, C., Jover, A., 2004. Immunohistochemical expression of estrogen receptor beta in normal and tumoral canine mammary glands.Vet Pathol 41, 269-272. Martin de las Mulas, J., Ordás, J., Millán, Y., Fernández-Soria, V., Ramón y Cajal, S., 2003. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat 80, 363-367. Martin, P.M., Cotard, M., Mialot, J.P., André, F., Raynaud, J.P., 1984. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother Pharmacol 12, 13-17. Mattei, M.G., Krust, A., Stropp, U., Mattei, J.F., Chambon, P., 1988. Assignment of the human progesterone receptor to the q22 band of chromosome 11. Hum Genet 78, 96-97. Misdorp, W., 1988. Canine mammary tumours: protective effect of late ovariectomy and stimulating effect of progestins. Vet Q 10, 26-33. Misdorp, W., 2002. Tumors of the mammary gland. In: Tumor in Domestic Animals, Fourth Ed. Blackwell, Iowa State, USA, pp. 575-606. Misdorp, W., Cotchin, E., Hampe, J.F., Jabara, A.G., von Sandersleben, J., 1971. Canine malignant mammary tumours. I. Sarcomas.Vet Pathol 8, 99-117. Misdorp, W., Else, R., Hellmén, E., Lipscomb, T.. 1999. Histologic Classification of Mammary Tumor of the Dog and Cat. In: World Health Organization International Histological Classification of Tumor of Domestic Animals, Second Ed. Armed Forces Institute of Pathology, Washington DC, USA, pp. 1-59. Misdorp, W., Hart, A.A., 1976. Prognostic factors in canine mammary cancer. J Natl Cancer Inst 56, 779-786. Misrahi, M., Atger, M., d'Auriol, L., Loosfelt, H., Meriel, C., Fridlansky, F., Guiochon-Mantel, A., Galibert, F., Milgrom, E., 1987. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem. Biophys. Res. Commun 143, 740-748. Moe, L., 2001. Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl 57, 439-443. Morris, J.S., Dobson, J.M., Bostock, D.E., 1993. Use of tamoxifen in the control of canine mammary neoplasia.Vet Rec 133, 539-542. Moulton, J.E., Rosenblatt, L.S., Goldman, M., 1986. Mammary tumors in a colony of beagle dogs. Vet Pathol 23, 741-749. Murua, E.H., Becker, K., Bullerdiek, J., Nolte, I., 2001. The canine ERBB2 gene maps to a chromosome region frequently affected by aberrations in tumors of the dog (Canis familiaris). Cytogenet Cell Genet 94, 194-195. Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., Akslen, L.A., Ragaz, J., Gown, A.M., Gilks. C.B., van de Rijn, M., Perou, C.M., 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 5367-5374. Nieto, A., Peña. L., Pérez-Alenza, M.D., Sánchez, M.A., Flores, J.M., Castaño, M., 2000. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 37, 239-47. Novosad, C.A., 2003. Principles of treatment for mammary gland tumors. Clin Tech Small Anim Pract 18, 107-109. Ooe, A., Takahara, S., Sumiyoshi, K., Yamamoto, H., Kawai, J., Shiba, E., 2012. Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Breast Dis 34, 9-17. Owen, L.N., 1980. The TNM Classification of Tumors in Domestic Animals, First Ed. World Health Organization, Geneva, USA. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F.L., Walker, M.G., Watson, D., Park, T., Hiller, W., Fisher, E.R., Wickerham, D.L.,Bryant, J., Wolmark, N., 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817-2826. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F.L., Watson, D., Bryant, J., Costantino, J.P., Geyer, C.E.J., Wickerham, D.L., Wolmark, N., 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24, 3726-3734. Peña, L.L., Nieto, A.I., Pérez-Alenza, D., Cuesta, P., Castaño, M., 1998. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 10, 237-246. Pérez Alenza, D., Rutteman, G.R., Peña, L., Beynen, A.C., Cuesta, P., 1998. Relation between habitual diet and canine mammary tumors in a case-control study. J Vet Intern Med 12, 132-139. Perou, C.M., S?rlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., L?nning, P.E., B?rresen-Dale, A.L., Brown, P.O., Botstein, D., 2000. Molecular portraits of human breast tumours. Nature 406, 747-752. Philibert, J.C., Snyder, P.W., Glickman, N., Glickman, L.T., Knapp, D.W., Waters, D.J., 2003. Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med 17, 102-106. Pichon, M.F., Broet, P., Magdelenat, H., Delarue, J.C., Spyratos, F., Basuyau, J.P., Saez, S., Rallet, A., Courriere, P., Millon, R., Asselain, B., 1996. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73, 1545-1551. Pierga, J.Y., Leroyer, A., Viehl, P., Mosseri, V., Chevillard, S., Magdelénat, H., 1996. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37, 57-64. Pietiläinen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V.M., Syrjänen, K., 1996. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122, 687-692. Priester, W.A., Mantel, N., 1971. Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 47, 1333-1344. Richards, H.G., McNeil, P.E., Thompson, H., Reid, S.W., 2001. An epidemiological analysis of a canine-biopsies database compiled by a diagnostic histopathology service. Prev Vet Med 51, 125-136. Rosenthal, R.C., 1995. Chemotherapy. In: Textbook of Veterinary Internal Medicine, Fourth Ed. W.B. Saunders Company, Philadelphia, USA, pp. 473-484. Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K.R., Stec, J., Ayers, M., Wagner, P., Morandi, P., Fan, C., Rabiul, I., Ross, J.S., Hortobagyi, G.N., Pusztai, L., 2005. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin Cancer Res 11, 5678-5685. Rudolph, P., Olsson, H., Bonatz, G., Ratjen, V., Bolte, H., Baldetorp, B., Fernö, M., Parwaresch, R., Alm, P., 1999. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications. J Pathol 187, 207-216. Rutteman, G.R., 1992. Hormones and mammary tumors in the bitch: a review. Tijdschr Diergeneeskd 117, 71-81. Rutteman, G.R., Misdorp, W., 1989. Canine mammary tumour disease: role of hormones in pathogenesis and treatment. Tijdschr Diergeneeskd 114, 34S-35S. Rutteman, G.R., Misdorp, W., Blankenstein, M.A., van den Brom, W.E., 1988. Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: differentreceptor profile in non-malignant and malignant states. Br J Cancer 58, 594-599. Rutteman, G.R., Willekes-Koolschijn, N., Bevers, M.M., Van der Gugten, A.A., Misdorp, W., 1986. Prolactin binding in benign and malignant mammary tissue of female dogs. Anticancer Res 6, 829-835. Sartin, E.A., Barnes, S., Toivio-Kinnucan, M., Wright, J.C., Wolfe, L.G., 1993. Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. Anticancer Res 13, 229-236. Sassi, F., Benazzi, C., Castellani, G., Sarli, G., 2010. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res 6, 5. Sato, O., Wada, T., Kawai, A., Yamaguchi, U., Makimoto, A., Kokai, Y., Yamashita, T., Chuman, H., Beppu, Y., Tani, Y., Hasegawa, T., 2005. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 103, 1881-1890. Schlüter, C., Duchrow, M., Wohlenberg, C., Becker, M.H., Key, G., Flad, H.D., Gerdes, J., 1993. The cell proliferation-associated antigen of antibody Ki-67: A very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123, 513-522. Schneider, R., Dorn, C.R., Taylor, D.O., 1969. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 43, 1249-1261. Scholzen, T., Dimmler, C., Wohlenberg, C., Flad, H.D., Gerdes, J., 1997. Novel splice forms of the Ki-67 mRNA. Eur J Cell Biol 72, 40-44. Scholzen, T., Gerdes, J., 2000. The Ki-67 Protein: From the Known and the Unknown. J Cell Physiol 182, 311-322. Selman, P.J., Mol, J.A., Rutteman, G.R., van Garderen, E., Rijnberk, A., 1994. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 134, 287-292. Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q., Juul, N., Leong, C.O., Calogrias, D., Buraimoh, A., Fatima, A., Gelman, R.S., Ryan, P.D., Tung, N.M., De Nicolo, A., Ganesan, S., Miron, A., Colin, C., Sgroi, D.C., Ellisen, L.W., Winer, E.P., Garber, J.E., 2010. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28, 1145-1153. Simon, D., Knebel, J.W., Baumgartner, W., Aufderheide, M., Meyer-Lindenberg, A., Nolte, I., 2001. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs. Am J Vet Res 62, 1825-1830. Slamon, D.J., Clark, G.M., 1994. Amplification of C-ERB-B2 and aggressive breast tumors? Science 240, 1795-1798. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712. Sleeckx, N., de Rooster, H., Veldhuis Kroeze, E.J., Van Ginneken, C., Van Brantegem, L., 2011. Canine mammary tumours, an overview. Reprod Domest Anim. 46, 1112-1131. Sonnenschein, E.G., Glickman, L.T., Goldschmidt, M.H., McKee, L.J., 1991. Body conformation, diet, and risk of breast cancer in pet dogs: a case-control study. Am J Epidemiol 133, 694-703. Sorenmo, K., 2003. Canine mammary gland tumors.Vet Clin North Am Small Anim Pract 33, 573-96. Sorenmo, K.U., Kristiansen, V.M., Cofone, M.A., Shofer, F.S., Breen, A.M., Langeland, M., Mongil, C.M., Grondahl, A.M., Teige, J., Goldschmidt, M.H., 2009. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence.Vet Comp Oncol 7, 162-172. S?rlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, H., Matese, J.C., Brown, P.O., Botstein, D., L?nning, P.E., B?rresen-Dale, A.L., 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98, 10869-10874. S?rlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., Perou, C.M., L?nning, P.E., Brown, P.O., B?rresen-Dale, A.L., Botstein, D., 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100, 8418-8423. Sotiriou, C., Neo, S.Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., Martiat, P., Fox, S.B., Harris, A.L., Liu, E.T., 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci 100, 10393-10398. Spyratos, F., Ferrero-Poüs, M., Trassard, M., Hacène, K., Phillips, E., Tubiana-Hulin, M., Le Doussal, V., 2002. Correlation between MIB-1 and other proliferation markers: Clinical implications of the MIB-1 cutoff value. Cancer 94, 2151-2159. Starborg, M., Gell, K., Brundell, E., Höög, C., 1996. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 109, 143-153. Stonecypher, M.S., Byer, S.J., Grizzle, W.E., Carroll, S.L., Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene 24, 5589-5605. Sunpaweravong, S., Snupaweravong, P., 2005. Recent Developments in Critical Genes in the Molecular Biology of Breast Cancer. Asian J Surg 28, 71-75. Theilen, G.H., Madewell, B.R., 1987. Clinical application of Cancer Chemotherapy. In: Veterinary Cancer Medicine, Second Ed. Lea and Febiger, Philadelphia, USA, pp. 183-196. Torrisi, R., Cardillo, A., Cancello, G., Dellapasqua, S., Balduzzi, A., Ghisini, R., Luini, A., Veronesi, P., Viale, G., Goldhirsch, A., Colleoni, M., 2010. Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer 10, 483-488. Trihia, H., Murray, S., Price, K., Gelber, R.D., Golouh, R., Goldhirsch, A., Coates, A.S., Collins, J., Castiglione-Gertsch, M., Gusterson, B.A., International Breast Cancer Study Group, 2003. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer 97, 1321-1331. Tsai, C.M., Chang, K.T., Wu, L.H., Chen, J.Y., Gazdar, A.F., Mitsudomi, T., Chen, M.H., Perng, R.P., 1996a. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56, 206-209. Urruticoechea, A., Smith, I.E., Dowsett, M., 2005. Proliferation Marker Ki-67 in Early Breast Cancer. J Clin Oncol 23, 7212-7220. van der Geer, P., Hunter, T., Lindberg, R.A., 1994. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10, 251-337. van Dierendonck, J.H., Keijzer, R., van de Velde, C.J., Cornelisse, C.J., 1989. Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells. Cancer Res 49, 2999-3006. van 't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536. van 't Veer, L.J., Paik, S., Hayes, D.F., 2005. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23, 1631-1635. Vegeto, E., Shahbaz, M.M., Wen, D.X., Goldman, M.E., O'Malley, B.W., McDonnell, D.P., 1993. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7, 1244-1255. Webster, N.J.G., Green, S., Jin, J.R., Chambon, P., 1988. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54, 199 -207. Wenger, C.R., Beardslee, S., Owens, M.A., Pounds, G., Oldaker, T., Vendely, P., Pandian, M.R., Harrington, D., Clark, G.M., McGuire, W.L., 1993. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28, 9-20. Yamagami, T., Kobayashi, T., Takahashi, K., Sugiyama, M., 1996a. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci 58, 1079-1083. Yamashita, H., Yando, Y., Nishio, M., Zang, Z., Hamaguchi, M., Mita, K., Kobayashi, S., Fuji, Y., Iwase, H., 2006. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13, 74-83. Yue, W., Wang, J.P., Li, Y., Bocchinfuso, W.P., Korach, K.S., Devanesan, P.D., Rogan, E., Cavalieri, E., Santen, R.J., 2005. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res 11, 925s-930s.
摘要: 乳腺瘤為母狗最常見的腫瘤之一,且約有半數病例為惡性。根據之前的研究,人類乳癌的分子表型或許可以做為犬惡性乳腺瘤的預後及化學療法反應評估。因此,本實驗目的在於利用人類乳癌的分子表型為犬惡性乳腺瘤分型,並分析分子表型於患犬與預後及化療反應的關係。病例來自於 49 隻患有惡性乳腺癌的患犬,利用免疫組織化學染色技術分析動情素受器(estrogen receptor, ER)、黃體助孕素受器(progesterone receptor, PR)、人類上皮生長因子受器-2(human epidermal growthfactor receptor 2, HER-2)及 Ki-67 的表現。所有樣本依照三種不同分類方式被分為五型、四型、或是三型分子表型。結果顯示無論在哪一種分類方式,在沒有接受化療的患犬中,為基底樣型(basal-like type)惡性乳腺瘤的患犬有較高臨床分期、腫瘤組織學惡性程度分級較高、較容易發生遠端轉移、以及擁有較低的存活率;此外,比較分子表型與存活率與化療反應的關係,患犬接受化療的存活率以有表現HER-2 的組別如五型中的 luminal B HER-2 positive 及 HER-2 overexpression,四型中的 luminal B 及 HER-2 overexpression,三型中的 HER-2 overexpression 較高。而即使接受化療,於 basal-like type 的患犬多數於一年內死亡。因此,我們推論犬隻惡性乳腺瘤的分子表現型,應可作為評估預後與化療反應的因子。
Canine mammary tumors (CMTs) are the most common neoplasm in female dogs and approximate half of them are malignant. Molecular phenotypes of human breast cancers (HBCs) might be used to correlate prognosis and chemotherapy response in dogs with malignant mammary tumors. Therefore, the aims of this study were to categorize malignant CMTs via molecular phenotype classification of HBCs and analyze the correlations between phenotypes, prognosis and chemotherapy response. Neoplastic specimens were obtained from 49 dogs with malignant CMTs and the expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 were detected by immunohistochemical staining. All samples were classified into three different kinds of classification including five types, four types, and three types of molecular phenotype. Results showed that regardless any kinds of classification, dogs without receiving chemotherapy in basal-like type were more likely to have advanced stage, high grade, distant metastasis, and shorter survival times. Besides, comparing overall survival rates with chemotherapy response in dogs with three different kinds of molecular phenotype classification in malignant CMTs, the survival rates were tended to be higher with overexpressing HER-2, that is, luminal B HER-2 positive and HER-2 overexpression types in 5 type, luminal B and HER-2 overexpression type in four type, and HER-2 overexpression type in three type of molecular phenotype. However, dogs with basal-like type tumor mostly died in one year follow-up even though they receiving chemotherapy. Therefore, it is suggested that molecular phenotypes in malignant CMTs may be suitable prognostic factors to survival and chemotherapy response.
URI: http://hdl.handle.net/11455/93040
其他識別: U0005-2506201515250100
文章公開時間: 10000-01-01
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.